DENVER, July 23,
2024 /PRNewswire/ -- PCM Trials and EmVenio Research,
a PCM Trials Company are pleased to announce the addition
of Jeff Huntsman to the leadership team as Chief
Commercial Officer. Jeff brings over 30 years of experience in
commercial planning, global business development, and scaling
organizations in the healthcare and life sciences industry.
This adds to the recent investment PCM Trials is making to
continue its growth in the clinical trial industry, creating the
most patient-centric clinical trial model available for hybrid and
decentralized clinical trials internationally. As
Chief Commercial Officer, Jeff will be leading our global
commercial organization and will be responsible for growing the
clinical trial services business formed by the combination of PCM
Trials and EmVenio Research.
"We are excited to have Jeff join the PCM Trials and EmVenio
teams," announced Greg Austin,
President of PCM. "His expertise in business development and growth
strategies will greatly benefit our success in the clinical trials
industry," Austin added.
"Jeff's proven track record in driving business growth and his
innovative approach to commercial strategy make him an invaluable
addition to our leadership team," said Thad
Wolfram, President of EmVenio. "We are confident that his
contributions will not only enhance our competitive edge but also
strengthen our commitment to making clinical trials more
accessible."
Most recently Jeff was Chief Commercial Officer at Sitero where
he established and led the global commercial organization and built
the sales and go to market strategies for their technologies and
services.
Prior to this, Jeff was an Advisor for a Healthcare Private
Equity, Warburg Pincus, where he helped carve out the Pharma
Intelligence business of Informa, PLC, and ultimately rebrand as
Citeline in June of 2022. Jeff was also the President at J-Boys
Consulting and has served in Executive Commercial leadership roles
at Clarivate Analytics, ConnectiveRx, and Parexel. Earlier in his
career, Jeff also held leadership roles at Liquent, Thomson
Reuters, and Rogers Medical Intelligence Solutions and started his
career at Stuart Pharmaceuticals (Astra Zeneca).
About PCM Trials
Since 2008, PCM Trials has led the
way in mobile research. Our Certified Mobile Research Nurses
(CMRNs) are driving the shift to patient-centric,
decentralized clinical trials, giving individuals the
flexibility to engage in research studies in the ways that work
best for them and expanding opportunities for participation. Since
then, PCM Trials has welcomed Clinical Trial Service (CTS) and
EmVenio Research to its family of companies, creating the most
patient-centric clinical trial model available for hybrid and
decentralized clinical trials internationally.
About EmVenio Research
EmVenio Research, a PCM Trials
Company, provides a scalable network of clinical trial sites
strategically located in underrepresented communities to engage a
diverse patient demographic. Our extensive global network comprises
highly skilled clinicians, leading principal investigators, and
cutting-edge research sites, allowing us to deliver high-quality
clinical research services that prioritize reducing the burden on
patient participation. Visit emvenio.com to learn
more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pcm-trials-and-emvenio-research-announce-the-appointment-of-jeff-huntsman-as-chief-commercial-officer-302203325.html
SOURCE EmVenio Research